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The Relationship between Neurological Disease
and Bullous Pemphigoid: A Population-Based
Case–Control Study
Sine´ad M. Langan1, Richard W. Groves1 and Joe West2
Previous small studies and case reports have suggested that neurological disorders may be associated with
bullous pemphigoid (BP). The objective of this study was to assess BP risk in patients with neurological diseases.
Computerized medical records from the Health Improvement Network, a large population-based UK general
practice database, were used to conduct a matched case–control analysis. Conditional logistic regression was
used to calculate odds ratios for specified neurological disorders. Comparing cases (n¼ 868) to controls
(n¼ 3,453), stroke was seen in 8 vs. 5%, odds ratio (OR) 1.8 (1.3–2.5); dementia in 7 vs. 2%, OR 3.4 (2.4–4.8);
Parkinson’s disease in 3 vs. 1%, OR 3.0 (1.8–5.0); epilepsy in 2 vs. 1%, OR 1.7 (1.0–3.0); and multiple sclerosis in
1 vs 0.1% (OR 10.7 (2.8–40.2). Estimates were not altered greatly when diagnoses up to 3 years before BP were
excluded, except the association with epilepsy was no longer significant. Significant associations were only
observed where neurological disease was diagnosed before the onset of pemphigoid. Study findings, except
the association with epilepsy, were robust to sensitivity analysis. Strong associations were observed between
specific neurological diseases and the later development of BP, supporting possible causal associations.
Mechanisms for disease occurrence based on these findings include immobility or age-related autoimmunity.
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INTRODUCTION
Bullous pemphigoid (BP) is the commonest bullous auto-
immune skin disease. It occurs in an elderly population with
median age of 80 years and is known to have significantly
associated increased mortality rates compared with the
general population. (Gudi et al., 2005; Joly et al., 2005;
Langan et al., 2008) The molecular basis for BP relates to
the development of autoantibodies against skin antigens. The
common antibodies in BP are BPAg1, in the intracellular part
of the hemidesmosome, and BPAg2, or type XVII collagen, a
transmembrane protein. The trigger for the development
of autoantibodies in BP is not fully understood. BPAg1 has
specific isoforms; one of which is specific to epithelium and
another to the nervous system. Recent studies show that
crossreactivity between these isoforms could be pathogenic
in BP. It is believed that exposure of the neuronal antigen
could lead to an immune reaction against the epithelial
isoform (Brown et al., 1995; Li et al., 2009). Previous studies,
which have not been population-based or adequately
controlled, show associations between neurological diseases
and later BP (Masouye´ et al., 1989; Chosidow et al., 2000;
Stinco et al., 2002; Kirschig et al., 1995). Table 1 sum-
marizes the studies other than case reports of associations
between neurological diseases and BP (Cordel et al., 2007;
Nielsen et al., 2008; Jedlickova et al., 2010). Cordel et al.
(2007) (n¼ 341 cases) reported a high prevalence of
dementia (prevalence 20, 95% confidence interval (CI)
16–25%), stroke (prevalence 15%, CI 4–19%), and Parkin-
son’s syndrome (prevalence 9, 95% CI 7–13%) in a case
series in France. The concurrent diagnosis of neurological
disorders means temporality was unclear. Similarly, Stinco
et al. (2005) (n¼238) reported associations between multiple
sclerosis (MS; n¼ 3) and Parkinson’s syndrome (n¼6;
prevalence ratio 62, 95% CI 12–594 comparing patients
hospitalized with BP to controls with trauma) with the
neurological pathology pre-dating BP. A case–control study
from France has assessed the associations between BP and
specific drugs and found significant associations between BP
and the use of neuroleptic drugs and aldosterone antagonists
(Bastuji-Garin et al., 1996). The size, unclear temporality,
and likely ascertainment bias limit the conclusions of these
studies. These associations are of interest as they may have a
role to have in the etiology of BP and may increase our
understanding of the basis for neurodegenerative disorders
both of which at present are poorly understood. Our aim was
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to test the hypothesis that there was an association between
previous neurological diseases and the later development of
BP in a large population-based case–control study and to
perform sensitivity analyses to assess whether this relation-
ship was likely to be causal.
RESULTS
Our cohort included incident 868 people with bullous
pemphigoid and 3,453 matched controls (Table 2). The
median (range) age at presentation for bullous pemphigoid
was 80 (23–102) years with similar age distribution in
controls, 79 (20–103) years. In all, 534 (62%) of cases were
female and identical proportions were seen in controls. Cases
had slightly higher overall comorbidity including neurologi-
cal diseases than controls with 311 (36%) having severe
comorbidity compared with 1,127 (32%) in controls. The
average follow-up before bullous pemphigoid diagnosis
or pseudodiagnosis was 3.9 years in cases and 4.2 years in
controls.
Table 3 shows the proportions of cases and controls with
neurological diseases by gender and age group.
Of 868 cases, neurological diseases were present as
follows: 73 (8%) previous stroke, 62 (7%) dementia, 26 (3%)
Parkinson’s disease, 19 (2%) epilepsy, and 8 (1%) had MS.
In the 3,469 controls, the proportions exposed were as
follows: stroke 171 (5%), dementia 81 (2%), Parkinson’s
disease 36 (1%), epilepsy 44(1%), and MS 3 (0.1%).
Table 4 shows the results of conditional logistic regression.
There was a 3-fold increase in the odds of pemphigoid with
dementia (odds ratio (OR) 3.4, 95% CI 2.4–4.8) and
Parkinson’s disease (OR 3.0, 95% CI 1.8–5.0). There was an
11-fold increase in odds of pemphigoid with MS, but the
CI was wide (OR 10.7, 95% CI 2.8–40.2). A 2-fold increase in
pemphigoid was seen with stroke (OR 1.8, 95% CI 1.3–2.5)
and epilepsy (OR 1.7, 95% 1.0–3.0).
Adjusting for comorbidity did not remove any of the
significant associations (Table 4). Healthcare utilization rates
were higher in cases than controls with 52% of cases
and 26% of controls having more than 12 consultations in the
year before BP diagnosis. Adjustment for utilization of health
services led to the association between BP and epilepsy
being no longer significant (adjusted OR 1.4 (0.7–2.7). The
association with dementia became stronger, adjusted OR 4.1
(2.7–6.3), whereas associations with stroke (adjusted OR 1.5
(1.1–2.2) and Parkinson’s disease (adj. OR 2.6 (1.4–4.7) were
reduced but persistently significant. The population attribu-
table fraction (PAF) was calculated for each neurological
disease and BP. The highest PAF was for stroke, which was
Table 1. Reports of neurological diseases associated with bullous pemphigoid
Study, year Location Number of cases Study design Disease association reported
Cordel et al.
(2007)
France 123 of 341 Case series from RCT Dementia 20% (CI 16–25%), n=68
Stroke 15% (CI 11–19%), n=52
Parkinson’s disease 9% (7–13%), n=32
MS/epilepsy/ALS/syringomyelia 5% (3–9%), n=19
Nielsen et al.
(2008)
Denmark 12 of 32,801 Population-based cohort of
MS patients
12 BP cases among 32,801 MS cases and relatives
Jedlickova et al.
(2010)
Czech Republic 38 of 89 Case–control study Any neurological disease in 43% BP vs. 18% controls
(other skin diseases)
Abbreviations: ALS, amyotrophic lateral sclerosis; BP, bullous pemphigoid; CI, confidence interval; MS, multiple sclerosis; RCT, randomized controlled trial.
Table 2. Demographic details of cases and controls
Characteristic
Bullous pemphigoid
cohort
Control
cohort
Gender
Male 334 (38%) 1,335 (38%)
Female 534 (62%) 2,134 (62%)
Age group (years), n (%)
o30 6 (1%) 26 (1%)
30–49 51 (6%) 198 (6%)
50–69 143 (16%) 602 (17%)
70–80 545 (63%) 2,206 (64%)
480 123 (14%) 437 (13%)
Diagnostic READ code, n (%)1
M145.00 528 (61%) NA
M145000 340 (39%) NA
Charlson comorbidity score, n (%)
None (0) 363 (42%) 1,622 (47%)
Moderate (1–2) 194 (22%) 720 (21%)
Severe (42) 311 (36%) 1,127 (32%)
Healthcare utilization, n (%)2
0 Visits 1 (0.1%) 277 (9%)
1–12 Visits 358 (48%) 2,000 (65%)
412 Visits 388 (52%) 803 (26%)
Abbreviation: NA, not applicable.
1Diagnostic READ codes are electronic codes used to capture medical
information: M145.00 ‘‘Pemphigoid’’, M145000 ‘‘Bullous pemphigoid’’.
2Including only individuals with more than 1-year follow-up before
diagnosis, 747 cases and 3,080 controls.
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6.7% of BP assuming a causal relationship. The other
neurological disorders were associated with the following
PAFs: Parkinson’s disease 0.6%, MS 0.9%, epilepsy 0.9%,
and dementia 5.1%.
The 3-year sensitivity analysis results are shown in Table 4.
All of the previous associations persisted after excluding
3 years except the association with epilepsy. Including only
individuals on specific therapy for neurological conditions
Table 3. Demographics of cases and controls with neurological disease
Stroke
(n=244), n (%)1
Dementia
(n=143), n (%)1
Epilepsy
(n=54), n (%)1
MS
(n=11), n (%)1
Parkinson’s disease
(n=62), n (%)1
Characteristic
Pemphigoid
(n=868)
Control
(n=3,469)
Pemphigoid
(n=868)
Control
(n=3,469)
Pemphigoid
(n=868)
Control
(n=3,469)
Pemphigoid
(n=868)
Control
(n=3,469)
Pemphigoid
(n=868)
Control
(n=3,469)
Sex 73 (8) 171 (5) 62 (7) 81 (2) 19 (2) 44 (1) 8 (1) 3 (0.1) 26 (3) 36 (1)
Male (n=1,662) 36 (11) 62 (5) 17 (5) 17 (1) 9 (3) 15 (1) 1 (0.3) 2 (0) 13 (4) 13 (1)
Female
(n=2,668)
37 (7) 109 (5) 45 (8) 64 (3) 10 (2) 29 (1) 7 (1) 1 (0) 13 (2) 23 (1)
Age group (years)
o30 (n=32) 0 0 0 0 0 1 (4) 0 0 0 0
30–49 (n=249) 1 (2) 2 (1) 0 0 3 (6) 2 (1) 1 (2) 0 0 0
50–69 (n=745) 6 (4) 5 (1) 1 (1) 0 1 (1) 9 (1) 4 (3) 1 (0) 0 1 (0)
70–89 (n=2,751) 56 (10) 129 (6) 48 (9) 51 (2) 13 (2) 30 (1) 3 (1) 2 (0) 23 (4) 31 (1)
490 (n=560) 10 (8) 35 (8) 13 (11) 30 (7) 2 (2) 2 (0) 0 0 3 (2) 4 (1)
Abbrevaition: MS, multiple sclerosis.
1The percentages represent the proportion of cases or controls within each category with the exposure of interest, i.e., 11% of males with bullous
pemphigoid had a previous stroke.
Table 4. Neurological and other diseases in patients with bullous pemphigoid
Disease
Cases
(n=868),
n (%)
Controls
(n=3,469),
n (%)
OR
(95% CI)
Univariate
P-value
Adjusted
OR
(95% CI)1
Including
only
individuals
on specific
medications
Adjusted
OR
(95%
CI)2
Cases,
n (%),
3 years
before
BP
Controls,
n (%),
3 years
before
BP
With
3-year
exclusion:
OR
(95% CI)
With
3-year
exclusion:
adjusted
OR
(95% CI)1
Neurological
Stroke 73 (8) 171 (5) 1.8 (1.3–2.5) o0.001 1.8 (1.3–2.4) NA 1.5 (1.1–2.2) 42 (5) 126 (3) 1.4 (1.0–2.1) 1.4 (0.9–2.1)
Dementia 62 (7) 81 (2) 3.4 (2.4–4.8) o0.001 3.3 (2.3–4.6) 2.4 (1.1–5.1) 4.1 (2.7–6.3) 33 (4) 43 (1) 3.3 (2.1–5.4) 3.2 (2.0–5.2)
Epilepsy 19 (2) 44 (1) 1.7 (1.0–3.0) 0.05 1.7 (1.0–2.9) 1.3 (0.9–1.8) 1.4 (0.7–2.7) 15 (2) 34 (1) 1.8 (1.0–3.2) 1.7 (0.9–3.1)
Multiple
sclerosis
8 (1) 3 (0.1) 10.7 (2.8–40.2) o0.001 Too few
data
6.1 (3.3–11.5) Too few
data
8 (1) 2 (0) 16.0 (3.4–75.3) Too few
data
Parkinson’s
disease
26 (3) 36 (1) 3.0 (1.8–5.0) o0.001 2.9 (1.7–4.9) 3.4 (2.1–5.4) 2.6 (1.4–4.7) 18 (2) 25 (1) 3.0 (1.6–5.5) 2.9 (1.5–5.4)
Other
Peptic ulcer
disease
39 (4) 179 (5) 0.9 (0.6–1.2) 0.71 Analysis
not
performed
Analysis
not
performed
Analysis
not
performed
Analysis
not
performed
Cancer 34 (4) 114 (3) 1.2 (0.8–1.8) 0.36
Connective
tissue diseases
29 (3) 131 (4) 0.9 (0.6–1.3) 0.64
Renal disease 162 (19) 573 (15) 1.2 (1.0–1.4) 0.12
Abbreviations: BP, bullous pemphigoid; CI, confidence interval; NA, not applicable; OR, odds ratio.
1Adjusted for Charlson scores not including neurological conditions.
2Adjusted for healthcare utilization.
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resulted in the association with Parkinson’s disease becoming
stronger OR 3.4 (95% CI 2.1–5.4). The associations with
dementia and MS were weaker but persistently significant,
OR 2.4 (95% CI 1.1–5.1) and 6.1 (95% CI 3.3–11.5),
respectively. The association with epilepsy was no longer
statistically significant once the analysis was restricted to
those on antiepileptic drugs, OR 1.3 (95% CI 0.9–1.8).
No association was detected with neurological disease
after the diagnosis of pemphigoid (data not shown). No
associations were seen between BP and diseases that were
not previously associated (Table 4). Specifically renal, peptic
ulcer, connective tissue disease, or cancer were not
associated with the later development of BP.
DISCUSSION
This is the first population-based case–control study examin-
ing the association between BP and neurological diseases.
The findings show a significant increase in the odds
of developing BP in people with neurological diseases
diagnosed more than 12 months previously. A 3-fold increase
in the odds of BP was seen with dementia and Parkinson’s
disease and a 2-fold increase for stroke and epilepsy. MS was
also associated with increased odds of BP although estimates
were somewhat imprecise.
These findings are coherent with the results of previous
case–control studies and case reports from many different
geographical regions, which report strong associations
between previous neurological diseases and the later devel-
opment of BP. Specific associations have been suggested
between BP and Parkinson’s disease, dementia, stroke, and
MS. Case series have also shown a high prevalence
of epilepsy in people with BP (Foureur et al., 2001). Recent
laboratory studies of BPAg1 isoforms in mouse models have
also added support to these associations being possibly
important in the etiology of BP.
Strengths and limitations
Our study is population-based and less susceptible to
selection and ascertainment bias than studies from tertiary
BP centers as our study represents diagnoses made across the
United Kingdom. In addition, examining unrelated diseases
we found no unexpected relationships with BP, lending
support to possible causal associations. Our study is at least
twice as large as previous studies, giving us power to exclude
chance as the basis for the study findings. Limited conclu-
sions should be drawn regarding the association with MS
because of small numbers. The use of routinely collected data
means that direct validation of diagnoses was not possible;
however, previous studies have confirmed the accuracy of
diagnoses in The Health Improvement Network. BP diagnosis
was made when a diagnostic READ code for BP was present.
It is not possible to know, given the data source, whether
immunopathology was used for diagnostic confirmation, yet,
if at all, this would have lead to non-differential misclassi-
fication and therefore to a null bias. Bullous pemphigoid is
uncommonly seen in general practice, and general practi-
tioners are unlikely to record this diagnoses without referral
to a dermatologist. We also previously confirmed that 94% of
our cases were being treated with either oral or potent topical
corticosteroids or a relevant steroid sparing agent after
diagnosis of BP or had evidence of referral to hospital, which
further supports the validity of the diagnosis (Langan et al.,
2008). Neurological diseases were defined as being present
if the READ code for that diagnosis was present 1 year or
more before BP diagnosis. Further analysis assessing only
those on specific treatments for dementia, Parkinson’s
disease, MS, and epilepsy showed persistence of all associa-
tions except the association between BP and epilepsy, which
was no longer statistically significant. Healthcare utilization
rates were higher in individuals with BP; however, adjusting
for utilization was associated with persistence of previously
observed associations with the exception of the association
between BP and epilepsy. Although there is a possibility of
overdiagnosis of neurological disease, this is less likely for BP
due to its rarity and specificity of diagnosis in secondary care.
It was also not possible to determine the severity of dementia
or the degree of functional impairment associated with
neurological disorders.
Implications for future research and clinical practice
The study findings lend weight to previous smaller clinical
and laboratory studies suggesting associations between
neurological disease and BP. The persisting findings despite
increasing the period of exclusion before BP onset and
adjusting for comorbidity lend weight to possible causality as
part of a multicausal model. (Rothman and Greenland, 2005)
If these findings were confirmed in a study from a tertiary
center with excellent diagnostic criteria but without being
broadly representative of the population, this would give
further support to possible causal associations. Neurological
diseases could only explain a small proportion of cases of BP
assuming causal relationships, i.e., stroke could account for
B6.7% of new BP cases based on the PAF.
Both BP and neurological diseases are more common with
increasing age. Degenerative neurological diseases could
lead to autoimmune triggers against neuronal BPAg1, leading
to later BP. This is supported by the association between the
dystonin gene, encoding for the neuronal isoform of BPAg1
and degenerative neurological disease in mice (Brown et al.,
1995). In order to explore a potential causative relationship
between neuronal damage and onset of pemphigoid, we
repeated our analysis looking for onset of neurological
disease after the diagnosis of pemphigoid (data not shown).
In this situation no association was seen, supporting the
contention that neuronal antigen exposure may be causa-
tively involved in the subsequent development of pemphi-
goid in patients with neurological disease. An alternative
mechanism for the association between previous neurologi-
cal disease and BP is that factors associated with the
management or outcomes of neurological disease, e.g., drugs
or immobility, may trigger the onset of BP. If our study and
previous studies had not consistently shown the temporal
association of neurological disease preceding BP, shared
risk factors between BP and neurological diseases
could be the basis for the association. Understanding the
basis for BP is important because of its associated mortality
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(Langan et al., 2008). Knowledge of the immunology of
neurodegenerative disorders might lead to new interventions,
e.g., targeting neuronal BPAg1. Further work is required
in a prospective elderly cohort with neurological examina-
tion and sera collection at the outset to determine whether
the predominant association with later BP is with neuro-
logical disease.
MATERIALS AND METHODS
The Health Improvement Network is a computerized longitudinal
general practice database with demographic data similar to the
general population. The version of the Health Improvement Network
we used contained data from 328 general practices that use the ‘‘In
Practice Vision’’ software (INPS, The Bread Factory, London, UK).
A number of studies have confirmed that the Health Improvement
Network data are sufficiently accurate for use in epidemiological
research. The quality of the Health Improvement Network data has
been validated against the General Practice Research database and
well-confirmed disease associations have been replicated (Lewis
et al., 2002; Bath-Hextall et al., 2007). Numerous studies have used
this approach for the purposes of identifying and studying a wide
range of diseases. A recent systematic review of validation studies in
the General Practice Research Database confirmed the accuracy and
appropriateness of this methodology (Herrett et al. 2010).
Study population
Between 1996 and 2006, we identified all individuals with READ
codes consistent with diagnoses of bullous pemphigoid from
the Health Improvement Network database. A control group of up
to four controls per case was selected, matched randomly by age,
sex, and general practice. Controls also had to be alive and
contributing data to the Health Improvement Network database on
the date of diagnosis of the matched case. A date of ‘‘pseudodiag-
nosis’’ was assigned to controls, which was the date of diagnosis for
the matched case.
Outcomes
Comprehensive lists of READ codes were assembled for stroke,
dementia, Parkinson’s disease, MS, and epilepsy. These lists were
manually checked by the authors and are available on request.
Outcome measures were ORs for the development of BP with stroke,
MS, Parkinson’s disease, and dementia before the diagnosis of BP.
The year before the diagnosis of BP was excluded in cases and
controls to reduce ascertainment bias.
Comorbidity
Comorbidity was defined by AIDS, diabetes mellitus, connective
tissue disease, heart failure, leukemia, lymphoma, liver disease,
myocardial infarction, cardiovascular disease, cancer, peptic ulcer
disease, peripheral vascular disease, and renal disease more than
3 months before the occurrence of BP.
Statistical analysis
Initially, the proportions of cases and controls with recorded
neurological diseases were identified. Conditional logistic regression
was then used to calculate ORs, and 95% CIs, to compare cases
and controls with respect to the specified neurological diseases.
Outcome measures were adjusted for comorbidity as determined
using Charlson scores excluding the diseases of interest in this work,
specifically dementia, hemiplegia, and stroke (Charlson et al., 1987).
Sensitivity analysis was carried out adjusting outcomes for over-
utilization of health services, determined by the number of total
visits per individual in the year before BP diagnosis, including only
individuals with 1-year follow-up before BP diagnosis. We counted
each unique day on which a medical diagnosis code was
entered into the database, and considered this to represent a general
practitioner visit. The median number of visits overall was
determined and the total number of visits per individual was then
converted into categories: 0 (no visits), 1 (between 1 and 12, the
median number of visits), and 2 (412, the median). Sensitivity
analyses were also carried out to ensure that observed associations
were not merely due to increased ascertainment. These included
repeating all analyses with an exclusion period of 3 years before the
diagnosis of BP and analyzing associations with diseases not
previously reported to be associated with BP (peptic ulcer disease,
cancer, connective tissue disease, and renal disease) to assess
whether similar associations were seen. Further sensitivity analyses
were undertaken repeating analyses including only individuals
on medications specific for the specified neurological condition,
e.g., donepezil for dementia and tizanidine hydrochloride for MS.
Analyses were repeated following BP diagnosis to assess temporality.
The PAF was calculated for each neurological disease and BP
assuming causal associations:
PAF ¼ PeðOR 1Þ
PeðOR 1Þ þ 1100
where Pe¼ proportion of exposed controls.
All statistical analyses were performed using STATA release 10.0
(Stata Corporation, College Station, TX).
Power
Assuming dementia is present in 2% of controls (Report for
Dementia UK 2007, King’s College London) and 5% of cases, this
study has 99% power to detect significant associations between
dementia and the later development of BP.
Ethical approval
Ethical approval has been obtained from the Nottingham Research
Ethics Committee (Reference number 07/Q2403/28).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
SML, RWG, and JW designed the study. SML and JW performed the data
analyses. All authors were involved in writing the manuscript. SML had full
access to all the data in the study and takes responsibility for the integrity of
the data and the accuracy of the data analysis. RWG acknowledges support
from the Department of Health via the National Institute for Health Research
(NIHR) comprehensive Biomedical Research Centre award to Guy’s and St
Thomas’ NHS Foundation Trust in partnership with King’s College London.
SML is funded by a fellowship from the British Association of Dermatologists.
JW is supported by a National Institute for Health Research Clinician Scientist
Fellowship.
REFERENCES
Bastuji-Garin S, Joly P, Picard-Dahan C et al. (1996) Drugs associated with
bullous pemphigoid. A case-control study. Arch Dermatol 132:272–6
www.jidonline.org 635
SM Langan et al.
Neurological Disease and Bullous Pemphigoid
Bath-Hextall F, Leonardi-Bee J, Smith C et al. (2007) Trends in incidence of
skin basal cell carcinoma. Additional evidence from a UK primary care
database study. Int J Cancer 121:2105–8
Brown A, Bernier G, Mathieu M et al. (1995) The mouse dystonia
musculorum gene is a neural isoform of bullous pemphigoid antigen 1.
Nat Genet 10:301–6
Charlson M, Pompei P, Ales K et al. (1987) A new method of classifying
prognostic comorbidity in longitudinal studies: development and
validation. J Chronic Dis 40:373–83
Chosidow O, Doppler V, Bensimon G et al. (2000) Arch Dermatol 136:
521–4
Cordel N, Chosidow O, Hellot M et al. (2007) Neurological disorders in
patients with bullous pemphigoid. Dermatology 215:187–91
Foureur N, Descamps V, Lebrun-Vignes B et al. (2001) Bullous pemphigoid in
a leg affected with hemiparesia: a possible relation of neurological
diseases with bullous pemphigoid? Eur J Dermatol 11:230–3
Gudi V, White M, Cruickshank N et al. (2005) Annual incidence and
mortality of bullous pemphigoid in the Grampian Region of North-east
Scotland. Br J Dermatol 153:424–7
Herrett E, Thomas SL, Schoonen WM et al. (2010) Validation and validity of
diagnoses in the General Practice Research Database: a systematic
review. Br J Clin Pharmacol 69:4–14
Jedlickova H, Hlubinka M, Pavlik T et al. (2010) Bullous pemphigoid and
internal diseases – A case-control study. Eur J Dermatol 20:96–101
Joly P, Benichou J, Lok C et al. (2005) Prediction of survival for patients with
bullous pemphigoid: a prospective study. Arch Dermatol 141:691–8
Kirtschig G, Walkden VM, Venning VA et al. (1995) Bullous pemphigoid and
multiple sclerosis: a report of three cases and review of the literature.
Clin Exp Dermatol 20:449–53
Langan SM, Smeeth L, Hubbard R et al. (2008) Bullous pemphigoid and
pemphigus vulgaris – incidence and mortality in the UK: population
based cohort study. BMJ 337:a180
Lewis J, Brensinger C, Bilker W et al. (2002) Validity and completeness of the
General Practice Research Database for studies of inflammatory bowel
disease. Pharmacoepidemiol Drug Saf 11:211–8
Li L, Chen J, Wang B et al. (2009) Sera from patients with bullous pemphigoid
(BP) associated with neurological diseases recognized BP antigen 1 in
the skin and brain. Br J Dermatol 160:1343–5.
Masouye´ I, Schmied E, Didierjean L et al. (1989) Bullous pemphigoid
and multiple sclerosis: more than a coincidence? Report of three cases.
J Am Acad Dermatol 21:63–8
Nielsen N, Frisch M, Rostgaard K et al. (2008) Autoimmune diseases in
patients with multiple sclerosis and their first-degree relatives: a
nationwide cohort study in Denmark. Mult Scler 14:823–9
Rothman K, Greenland S (2005) Causation and causal inference in
epidemiology. Am J Public Health 95(Suppl 1):S144–50
Stinco G, Mattighello P, Zanchi M et al. (2002) Multiple sclerosis and bullous
pemphigoid: a casual association or a pathogenic correlation? Eur J
Dermatol 2:186–8
Stinco G, Codutti R, Scarbolo M et al. (2005) A retrospective epidemiological
study on the association of bullous pemphigoid and neurological
diseases. Acta Derm Venereol 85:136–9
636 Journal of Investigative Dermatology (2011), Volume 131
SM Langan et al.
Neurological Disease and Bullous Pemphigoid
